US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors
Datar Cancer Genetics Inc that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™-Glio'.
Datar Cancer Genetics Inc that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra™-Glio'.